CRP and rheumatoid arthritis: In clinical studies, RA patients were treated with 4–8 mg/kg intravenous doses or the 162 mg weekly and every other weekly subcutaneous doses of ACTEMRA; the levels of CRP decreased to within the normal range along with changes in the pharmacodynamic parameters (i.e. decrease in rheumatoid factor, erythrocyte sedimentation rate (ESR), serum amyloid A, fibrinogen; and increase in haemoglobin) [9].